Top

Published in:

01-08-2019 | Anticoagulant | Original Article

Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients

Authors: Han Guo, Yuncong Zhang, Aiwei Li, Chanjuan Wang, Shuo Yang, Yinmei Zhang, Jie Zhang, Rui Qiao

Published in: Clinical and Experimental Medicine | Issue 3/2019

Abstract

Lupus anticoagulant (LA) is considered a risk factor for thromboembolism (TE) and adverse pregnancy outcomes (APOs). However, quite a few patients diagnosed with LA positivity do not suffer these adverse events. Further testing of anticardiolipin (aCL), anti-beta2-glycoprotein I (anti-β2GPI) or anti-domain 1 of β2GPI (anti-D1) may help to assess the occurrence risk of TE and APOs. Therefore, we aimed to study how to stratify LA-positive patients. In our study, 167 LA-positive patients were consecutively enrolled from January 2015 to December 2016. Serum aCL and anti-β2GPI (IgG, IgM and IgA) and anti-D1 IgG were simultaneously measured. Among these patients, 114 (68.3%) were followed for an average of 36.5 months for TE and APOs. The outcomes showed that 105 patients experienced TE and/or APOs, and 62 patients were LA carriers. Anti-D1 had good consistency with triple positivity (LA+, aCL+, anti-β2GPI+) (kappa = 0.742). Elevated anti-D1 was related to increased risks for TE [odds ratio (OR) 29.87, 95% confidence interval (CI) 8.05–110.74] and APOs (OR 8.73, 95% CI 3.41–22.31). Area under curve showed that the diagnostic power of anti-D1 for TE and APOs was 0.856 (95% CI 0.743–0.970) and 0.682 (95% CI 0.599–0.765), respectively. Survival analysis revealed that patients with high anti-D1 titres had a high cumulative incidence of APOs (hazard ratio 4.66, 95% CI 1.46–14.87). In conclusion, anti-D1, based on good consistency with triple positivity in LA-positive patients, has a stronger association with TE and APOs and, to some degree, could predict pregnancy outcomes. Therefore, anti-D1 may aid risk stratification in LA-positive patients.

Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306. https://doi.org/10.1111/j.1538-7836.2006.01753.x.CrossRefPubMed

Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7:330–9.CrossRefPubMed

Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033–44.CrossRefPubMed

Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012;64:2311–8. https://doi.org/10.1002/art.34402.CrossRefPubMedPubMedCentral

Yelnik CM, Laskin CA, Porter TF, et al. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med. 2016;3:e000131. https://doi.org/10.1136/lupus-2015-000131.CrossRefPubMedPubMedCentral

Gebhart J, Posch F, Koder S, et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood. 2015;125:3477–83. https://doi.org/10.1182/blood-2014-11-611129.CrossRefPubMed

Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8:998–1005. https://doi.org/10.1016/S1474-4422(09)70239-X.CrossRefPubMed

Pengo V, Biasiolo A, Gresele P, et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol. 2007;27:e309–10. https://doi.org/10.1161/ATVBAHA.107.153536.CrossRefPubMed

Bertolaccini ML, Amengual O, Andreoli L, et al. 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13:917–30. https://doi.org/10.1016/j.autrev.2014.05.001.CrossRefPubMed

10.

de Groot PG, Urbanus RT. The significance of autoantibodies against beta2-glycoprotein I. Blood. 2012;120:266–74. https://doi.org/10.1182/blood-2012-03-378646.CrossRefPubMed

11.

de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep. 2011;13:70–6.CrossRefPubMed

12.

de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105:1540–5. https://doi.org/10.1182/blood-2004-09-3387.CrossRefPubMed

13.

de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7:1767–73. https://doi.org/10.1111/j.1538-7836.2009.03588.x.CrossRefPubMed

14.

Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost. 2015;13:782–7. https://doi.org/10.1111/jth.12865.CrossRefPubMed

15.

Pericleous C, Ruiz-Limon P, Romay-Penabad Z, et al. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology. 2015;54:722–7. https://doi.org/10.1093/rheumatology/keu360.CrossRefPubMed

16.

Agostinis C, Durigutto P, Sblattero D, et al. A non–complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014;123:3478–87. https://doi.org/10.1182/blood-2013-11-537704.CrossRefPubMed

17.

Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7:833–42. https://doi.org/10.1111/j.1538-7836.2009.03316.x.CrossRefPubMed

18.

Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2009;7:1737–40. https://doi.org/10.1111/j.1538-7836.2009.03555.x.CrossRefPubMed

19.

de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood. 2007;109:1490–4. https://doi.org/10.1182/blood-2006-07-030148.CrossRefPubMed

20.

Amengual O, Forastiero R, Sugiura-Ogasawara M, et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus. 2017;26:266–76. https://doi.org/10.1177/0961203316660203.CrossRefPubMed

21.

Lee JS, Gu J, Park HS, Yoo HJ, Kim HK. Coexistence of anti-beta2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk. Clin Chem Lab Med. 2017;55:882–9. https://doi.org/10.1515/cclm-2016-0676.CrossRefPubMed

22.

Bertolaccini ML, Sciascia S, Murru V, Garcia-Fernandez C, Sanna G, Khamashta MA. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. Thromb Haemost. 2013;109:207–13.CrossRefPubMed

23.

Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504–12. https://doi.org/10.1002/art.33340.CrossRefPubMed

24.

Oku K, Amengual O, Atsumi T. Antiphospholipid scoring: significance in diagnosis and prognosis. Lupus. 2014;23:1269–72. https://doi.org/10.1177/0961203314537361.CrossRefPubMed

25.

De Craemer AS, Musial J, Devreese KM. Role of anti-domain 1-beta2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost. 2016;14:1779–87. https://doi.org/10.1111/jth.13389.CrossRefPubMed

26.

Iwaniec T, Kaczor MP, Celinska-Lowenhoff M, Polanski S, Musial J. Clinical significance of anti-domain 1 beta2-glycoprotein I antibodies in antiphospholipid syndrome. Thromb Res. 2017;153:90–4. https://doi.org/10.1016/j.thromres.2017.02.019.CrossRefPubMed

27.

Chighizola CB, Pregnolato F, Andreoli L, et al. Beyond thrombosis: anti-beta2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J Autoimmun. 2018;90:76–83. https://doi.org/10.1016/j.jaut.2018.02.002.CrossRefPubMed

28.

Chighizola CB, Pregnolato F, Andreoli L, et al. Autoantibodies specific to a peptide of beta2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood. 2012;120:3360–70. https://doi.org/10.1182/blood-2011-09-378851.CrossRef

Title: Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients
Authors: Han Guo
Yuncong Zhang
Aiwei Li
Chanjuan Wang
Shuo Yang
Yinmei Zhang
Jie Zhang
Rui Qiao
Publication date: 01-08-2019
Publisher: Springer International Publishing
Keywords: Anticoagulant
Antiphospholipid Syndrome
Antiphospholipid Syndrome
Published in: Clinical and Experimental Medicine / Issue 3/2019
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-019-00555-w

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

Neutrocyte-to-lymphocyte ratio predicts the presence of a replicative hepatitis C virus strand after therapy with direct-acting antivirals

Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile

Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study

Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients

Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer

Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page